Securities code: 002589 securities abbreviation: Realcan Pharmaceutical Group Co.Ltd(002589) Announcement No.: 2022-007 Realcan Pharmaceutical Group Co.Ltd(002589)
Announcement on the resolutions of the 17th meeting of the 4th board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements and major omissions.
Realcan Pharmaceutical Group Co.Ltd(002589) (hereinafter referred to as “the company”) the notice of the 17th meeting of the Fourth Board of supervisors was issued in writing on January 17, 2022 and held by on-site voting in the conference room on the fourth floor of the company, No. 326 Airport Road, Yantai on the morning of January 21, 2022. The meeting was presided over by Wu Liyan, chairman of the board of supervisors. Three supervisors should attend the meeting and three actually attended the meeting. The meeting was held in accordance with the company law of the people’s Republic of China and the articles of association. After deliberation by the attending supervisors, the following resolutions were reached at the meeting: I. the proposal on the renewal of the appointment of accounting firms was deliberated and adopted
Tianyuanquan Certified Public Accountants (special general partnership) adheres to the principle of independent audit in the process of practice, can issue various professional reports for the company on time, and the contents of the reports are objective and fair. We agree to renew the appointment of tianyuanquan Certified Public Accountants (special general partnership) as the company’s audit institution in 2021.
The proposal was adopted by 3 votes in favor, 0 against and 0 abstention.
This proposal needs to be submitted to the first extraordinary general meeting of shareholders of the company in 2022 for deliberation.
2、 The proposal on using idle self owned funds to purchase financial products was deliberated and adopted
The use of idle self owned funds to purchase financial products is conducive to improving the use efficiency of funds, obtaining certain investment benefits, will not affect the normal development of the company’s main business, and is in line with the interests of the company and all shareholders. There is no situation that damages the interests of the company and all shareholders, especially small and medium-sized shareholders. The decision-making and deliberation procedures for this matter are legal and compliant. It is agreed that the company shall use idle self owned funds with a limit of no more than 1 million yuan to purchase financial products.
The proposal was adopted by 3 votes in favor, 0 against and 0 abstention.
It is hereby announced.
Realcan Pharmaceutical Group Co.Ltd(002589) board of supervisors
January 24, 2022
